Impact of body composition on outcome in patients with early breast cancer
Open Access
- 25 September 2017
- journal article
- research article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 26 (3) , 861-868
Abstract
Purpose We investigated the impact of body composition on outcomes of patients with early breast cancer. Skeletal muscle mass, visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), and muscle fat infiltration or inter-muscular adipose tissue areas (IMAT), obtained by computed tomography (CT), were assessed. Methods A total of 119 female patients who had breast cancer were included in this retrospective study. The total skeletal muscle and fat tissue areas were evaluated in two adjacent axial slices obtained at the third lumbar vertebra by CT used for disease staging. The women were assigned to either a sarcopenia or non-sarcopenia group based on their skeletal muscle index (cut-off 41.0 cm2/m2). They also were classified into high and low VAT/SAT ratio groups and assigned to either the high or low IMAT index group. The association of the body composition parameters and prognosis was statistically analyzed. Results Among the 119 evaluable patients, 58 were sarcopenic (48.8%), 55 (46.2%) had a high VAT/SAT ratio, and 62 (52.1%) had a high IMAT index. Median follow-up was 52.4 months. Multivariate analysis revealed sarcopenia and IMAT index as independent prognostic factors for disease-free survival (p = 0.02 and p = 0.04, respectively) and overall survival (p = 0.05 and p = 0.02, respectively). BMI was not significantly associated with disease-free survival, but a trend was observed (p = 0.09). Conclusions Sarcopenia and IMAT index are independent prognostic factors in early breast cancer; therefore, assessing body composition could be a simple and useful approach to integrate into patient management.Keywords
This publication has 34 references indexed in Scilit:
- Impact of body mass index (BMI) on the prognosis of high-risk early breast cancer (EBC) patients treated with adjuvant chemotherapyBreast Cancer Research and Treatment, 2016
- Sarcopenic obesity: A probable risk factor for dose limiting toxicity during neo-adjuvant chemotherapy in oesophageal cancer patientsClinical Nutrition, 2016
- Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patientsJournal of Cachexia, Sarcopenia and Muscle, 2016
- Impact of body fat distribution on neoadjuvant chemotherapy outcomes in advanced breast cancer patientsCancer Medicine, 2015
- Imaging body composition in cancer patients: visceral obesity, sarcopenia and sarcopenic obesity may impact on clinical outcomeInsights into Imaging, 2015
- Clinical nutrition guidelines of the French Speaking Society of Clinical Nutrition and Metabolism (SFNEP): Summary of recommendations for adults undergoing non-surgical anticancer treatmentDigestive and Liver Disease, 2014
- Overweight and obesity as poor prognostic factors in locally advanced breast cancer patientsBreast Cancer Research and Treatment, 2014
- Body fat composition impacts the hematologic toxicities and pharmacokinetics of doxorubicin in Asian breast cancer patientsBreast Cancer Research and Treatment, 2014
- Quantification of the visceral and subcutaneous fat by computed tomography: Interobserver correlation of a single slice techniqueDiagnostic and Interventional Imaging, 2013
- Prevalence and prognostic effect of sarcopenia in breast cancer survivors: the HEAL StudyJournal of Cancer Survivorship, 2012